A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Adolescent Participants (12 Years to Less Than 18 Years) With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Adolescent Participants (12 Years to Less Than 18 Years) With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis
Inclusion Criteria
Participants must have stable plaque psoriasis for 6 months or more prior to Screening.
Participants must have moderate to severe psoriasis defined by:.
i) Psoriasis Area and Severity Index (PASI) ≥ 12, at screening visit and Day 1.
ii) Static Physician's Global Assessment (sPGA) ≥ 3, at screening visit and Day 1.
iii) Body Surface Area (BSA) ≥ 10% involvement, at screening visit and Day 1.
- A female (as assigned at birth) participant is eligible to participate if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies:.
i) Is not an individual of childbearing potential (IOCBP).
ii) Is an IOCBP and using a contraceptive method that is highly effective (with a failure rate of < 1% per year) during the study intervention period and for at least 3 days after discontinuation of the study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction for the same period.
Exclusion Criteria
Clinical.Trials@bms.com855-907-3286
Walnut Creek, California 94598, United States
Tampa, Florida 33607, United States
Goodlettsville, Tennessee 37072, United States
Ciudad Autonoma de Buenos Aires, Buenos Aires 1425, Argentina
1545404644
Ciudad Autonoma de Buenos Aires, Buenos Aires C1425DKG, Argentina
5401148238755
SAN M. de Tucuman, Tucumán Province T4000AXL, Argentina
381 5537821
Liège, 4000, Belgium
Ribeirão Preto, São Paulo 14051-140, Brazil
Beijing, Beijing Municipality 100045, China
Bogota, Cundinamarca 111 411, Colombia
Szeged, Csongrád megye 6720, Hungary
Budapest, Pest County 1033, Hungary
+3612108139
Roma, 00168, Italy
Kaohsiung Niao Sung Dist, Kaohsiung 83301, Taiwan
886 77317123 x2426
510-599-4750
310-337-7171
818-350-7483
507-261-3758
303-463-1947
954-849-0902
305-707-9852
786-483-7856
813-948-7550
813-974-4381
770-733-1077
404-939-9220
317-516-5030
301-355-3183
000-000-0000
248-884-5356
913-451-7546
702-596-6137
14404404430440
440-940-2739
215-563-7330
615-241-2820
210-704-4037
425-275-4404
+5491154140381
+5491168360026
0054115236-4056
5491154583202
3227641472
003293322287
+3243237232
+5551993785952
551636022302
587-487-0187
709-728-1563
2269197887
905-889-2005
(416) 869-3376
13370115021
18618269437
13681438841
13923848084
0310-3962009
18637110289
073185356114
+86 18017336636
13750837205
0049-251-8356558
00496131 9722360
030450618343
+493514583401
091318533861
36304723487
+3652255204
39 0630154227
3339549360
+522299314102
48722266055
0048883251755
0048603544222
+48895134629
+48601986646
00 48 601 316 460
0000000000
0040760930352
0040746743561
0743813380
40752976613
936009733(ext.70034)
+34935537007
+34620408898
34917792260
0034981956011
886-7-3422121x74300
886223123456
886975360157